SLBTHealthcare · Biotechnology

SLBT Stock Forecast: SL Science Holding Ltd. Price Predictions for 2026-2027

Last close, 8 Oct 2026

$1.52

+0.66% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 8 Oct 2026 — in the weakest quartile.

Market cap

$846.7M

Ticker Nerd rank

1 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

−5.0%

−42.0%

From high

−86.2%

From low

+0.7%

$11

Range since 9 June 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

SLBT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SL Science Holding Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026

1 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Momentum

Revisions

Accruals

Value

Volatility

Growth

Quality

Issuance

Size (46): Smaller than most of the companies we track.

Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SLBT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SLBT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 9 June 2026Adjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SLBT appears on the weeks it earns a place.

Performance

SLBT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

SLBT vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SLBT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

SL Science Holding Ltd. (SLBT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: —
Price / sales: 258.9×
Price / book: 1.2×
EV / EBITDA: −1.1×

Growth & margins

Revenue growth (YoY): −7.6%
Earnings growth (YoY): —
Gross margin: —
Operating margin: −142.6%
Net margin: −72.5%

Returns & dividend

Return on equity: −167.2%
Return on assets: −135.6%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

SL Science Holding Ltd. (SLBT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

SL Science Holding Ltd. has a market value of $846.7M and an enterprise value of $2.5M.
Shares outstanding: 560.8M.
Forward dividend yield: 0.00%, paying out 0% of earnings.
SL Science Holding Ltd. employs 14 people.

market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

SLBT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
SLBTSL Science Holding Ltd.	$846.7M	1
ODTXOdyssey Therapeutics, Inc.	$854.8M	1
CRVSCorvus Pharmaceuticals, Inc.	$855.3M	54
TBPHTheravance Biopharma, Inc.	$857.7M	—
SANASana Biotechnology, Inc.	$835.2M	31
GLUEMonte Rosa Therapeutics, Inc.	$871.8M	63
AVBPArrivent BioPharma, Inc.	$823.9M	30

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SL Science Holding Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SLBT news & analysis

SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma

GlobeNewsWire · 24 Sept 2026positive

SL Science presented preclinical data at the 85th Annual Meeting of the Japanese Cancer Association showing that γδ T cells target chemotherapy-resistant glioblastoma. The findings indicate the therapy can preferentially destroy MGMT-positive tumor cells, the population that survives standard treatment and drives recurrence.

Why it matters — The data highlight SLBT's γδ T-cell therapy as potentially addressing chemotherapy-resistant glioblastoma, a key area of unmet medical need relevant to the company's pipeline.

SL Science: A $1.15 Billion Valuation Built On Preclinical Promises

Seeking Alpha · 16 Sept 2026negative

Seeking Alpha rates SL Science Holding Limited as a Sell, citing an unsustainable $1.15 billion valuation based on a strictly preclinical pipeline that has not entered human trials. The company has only $9 million in cash, a $3.82 million annual loss, and going-concern doubts, making imminent dilution likely absent a major partnership.

Why it matters — SLBT watchers would care because the article highlights financial and clinical risks around the company's valuation, cash runway, and preclinical-stage Gamma Delta T cell therapy.

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

GlobeNewsWire · 2 Sept 2026positive

SL Science Holding Limited's management team rang the Nasdaq bell at the Nasdaq MarketSite in Times Square, New York, to mark the company's first quarter as a publicly traded company. The Taiwan-headquartered biomedical firm specializes in developing cellular and gene therapies.

Why it matters — The Nasdaq bell-ringing is a notable milestone that highlights SLBT's early progress and visibility since its public listing, of interest to those tracking the company's development.

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

GlobeNewsWire · 27 Aug 2026positive

SL Science highlighted the filing of a new Drug Master File (DMF number 044612) with the U.S. FDA covering exosomes derived from Gamma Delta T (GDT) cells. The DMF was filed by JY BioMed Co., Ltd., the intellectual property holder of the GDT platform and SL Science's licensor, expanding the regulatory foundation of the company's platform.

Why it matters — A SLBT watcher would care because the filing expands the regulatory foundation of the GDT cell-derived exosome platform underlying SL Science's cellular and gene therapy business.

FAQ

Frequently asked questions about SLBT stock

How does Ticker Nerd's model rank SLBT?

As at 8 Oct 2026, SL Science Holding Ltd. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (46 of 100).

What is the SLBT stock forecast for 2030?

No analyst covering SL Science Holding Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLBT are extrapolating price history, which says nothing about the business.

What does SL Science Holding Ltd. do?

SL Science Holding Ltd. is a biomedical company focused on cell therapy, exosome products, and cellular and gene therapies.

What is the latest news on SLBT?

The most recent item we track (GlobeNewsWire, 24 Sept 2026): "SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma". SL Science presented preclinical data at the 85th Annual Meeting of the Japanese Cancer Association showing that γδ T cells target chemotherapy-resistant glioblastoma. The findings indicate the therapy can preferentially destroy MGMT-positive tumor cells, the population that survives standard treatment and drives recurrence.

Company

About SL Science Holding Ltd.

SL Science Holding Ltd. is a biomedical company focused on cell therapy, exosome products, and cellular and gene therapies. The company develops and commercializes proprietary platforms and related solutions across its main business segments, including Exosome products, CD-19 Armed-T products, and GDT cell therapy products. Its offerings include immune cell development services, skincare product formulations, and milk-derived exosome-based products, reflecting a combination of life sciences and applied biotechnology applications. Based in Taipei, Taiwan, SL Science Holding Ltd. serves the broader healthcare and biotechnology market by advancing technologies used in regenerative medicine, cancer-related research, and specialty bioactive products. The company positions its proprietary GDT platform and related technologies at the center of its current operations, supporting standardized and scalable approaches within the cell therapy field.

CEO Mr. Ching-Dong Wang · 14 employees · Taiwan · https://www.sl-bio.com